Medical/Pharmaceuticals
Bioptimus Unveils M-Optimus, a World Model for Biology
Revolutionary model represents a transformative step toward AI-powered virtual tissues, patient digital twins, and a new era of data-driven biomedical innovation * The Unveiling of M-Optimus: Bioptimus has trained its inaugural World Model for biology - a foundation model that learns interacti...
2025-12-17 20:00
CUHK and MicroSigX partner to launch a breakthrough test aiding early autism diagnosis offering 200 free test quotas
HONG KONG, Dec. 17, 2025 /PRNewswire/ -- The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) announced the official launch of the world's first "AI-Powered Multikingdom Microbial Biomarkers Technology" (MSX Metagenie®) today, in collaboration with MicroSigX Biotech Diag...
2025-12-17 19:01
183
Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the U.S. Food and Drug Administ...
2025-12-17 16:10
556
Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
SHANGHAI and HONG KONG, Dec. 17, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2025-12-17 09:00
187
Aussie medtech Ferronova raises another $6 million to advance image-guided cancer surgery
ADELAIDE, Australia, Dec. 17, 2025 /PRNewswire/ -- Australian company Ferronova has raised a further$6 million to progress the commercialisation of a novel nanoparticle image-guided surgery solution seeking to improve identification of cancer cells and reduce the risk of undetected recurrence fol...
2025-12-17 08:30
192
Jiaying Pharmaceutical: A New Pathway for the Industrialization of Century-Old Hakka Medicine
HONG KONG, Dec. 17, 2025 /PRNewswire/ -- Recently, Meizhou in Guangdong, known as the "World Capital of the Hakka", welcomed a globally watched event, the Seventh World Hakka Entrepreneurs Convention. At this gathering that drew the attention of Hakka entrepreneurs worldwide, Guangdong Jiaying Ph...
2025-12-17 08:00
137
KPM Analytics Unveils the SmartChem® 800 Series, a Next-Generation Platform for High-Throughput Wet Chemistry
Industry's highest-capacity discrete analyzer delivers true walk-away automation for commercial laboratories WESTBOROUGH, Mass., Dec. 16, 2025 /PRNewswire/ -- Commercial laboratories face mounting pressure to process more samples with fewer staff while maintaining fast turnaround times. When urg...
2025-12-16 22:00
839
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
* The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters * Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials ...
2025-12-16 08:30
1021
NYSE Content Advisory: Pre-Market Update + Seven of the Top 10 IPOs in 2025 List on NYSE
NEW YORK, Dec. 15, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on December 15th ...
2025-12-15 22:10
1374
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE for obesit...
2025-12-15 21:00
1321
MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
The company is revolutionizing regenerative healthcare through innovation,
clinical alignment, and GMP-grade excellence acrossSoutheast Asia
SAN ANTONIO, Dec. 15, 2025 /PRNewswire/ -- Frost & Sullivan
2025-12-15 17:00
1131
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing. - ASC50 had strong target engagement after a single oral dose, in...
2025-12-15 17:00
1538
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
* Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient * The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressu...
2025-12-15 15:02
1126
Manulife and Bupa Sign MoU for Strategic Collaboration in Hong Kong to Create a More Robust, Integrated Healthcare Network Offering Customers Greater Access and Choice
HONG KONG, Dec. 15, 2025 /PRNewswire/ -- Manulife (International) Limited ("Manulife") and Bupa International Limited ("Bupa") are pleased to announce today the signing of a Memorandum of Understanding ("MoU"), intended to establish a strategic collaboration inHong Kong that will provide customer...
2025-12-15 13:45
1651
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the launch of its 2030 Strategy, out...
2025-12-15 12:40
1552
AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- AbbVie ASEAN has been ranked #15 in
the inauguralFortune Best Companies to Work For Southeast Asia 2025 list, in
partnership with Great Place To Work®, highlighting workplaces acrossSingapore,
Malaysia, Thailand and the Philippines.
2025-12-15 09:00
1308
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Announcement Highlights: * Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. * The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CY...
2025-12-15 08:25
1149
ALL CONEC Signs MOU with MINIMAX to Accelerate Global Digital Dental Expansion
SEOUL, South Korea, Dec. 13, 2025 /PRNewswire/ -- ALL CONEC has signed a memorandum of understanding (MOU) with Australian digital dental company MINIMAX to jointly promote digital implant production, marking a strategic move to expand into global markets. The collaboration will validate implant...
2025-12-13 08:00
2683
TraceLink Supports UNICEF's Traceability and Verification System (TRVST) to Advance Safe, Authentic Medicine Access Globally
TraceLink announced its support for UNICEF's Traceability and Verification System (TRVST), a global initiative improving the safety, authenticity, and traceability of medicines in regions vulnerable to falsified or substandard products. By supporting TRVST, TraceLink reinforces its position as th...
2025-12-12 00:21
2634
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization - Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-bindin...
2025-12-11 23:57
1653
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Synvo AI and Sobat Bisnis Group (SBG) Forge Strategic Partnership to Bring Secure, Context-Aware Enterprise AI to Indonesia and Southeast Asia
[Picked up by 290 media titles]
2025-12-16 08:00
Colebrook Bosson Saunders Chooses India for First Executive Dialogue Exploring Future of Workspaces and Technology
[Picked up by 287 media titles]
2025-12-16 14:26
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
